KNSA Stock — Kiniksa Pharmaceuticals International plc: Cash, EV, Pipeline

What they do

We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.

Source: 10-K FY2025 via SEC EDGAR

Share price

$93.86

Market cap

$7,374.7M

Cash

$568.8M

Enterprise value

$6,805.9M

Balance sheet

Cash	$568.8M
Debt	$0.0M
Net cash	$568.8M
Enterprise value	$6,805.9M
Basic shares	78.0M shares
Fully diluted shares	90.0M shares
Fully diluted market cap	$8,447.7M
Cash per share	$7.29
Quarterly burn	+$50.2M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

78.0M

Pre-funded warrants

0.0M

Options

8.8M

RSUs

2.4M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.8M

FDSO

90.0M

Cap table as of 2026-07-24.

Price history

Loading KNSA daily closes…

Loading price history…

Next catalyst

KPL-387 · Feb 11 - Mar 24 in 15 mo · Phase 3 · Pericarditis; Pericarditis Acute; Recurrent Pericarditis

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 11 - Mar 24 in 15 mo	KPL-387	Phase 3	Pericarditis; Pericarditis Acute; Recurrent Pericarditis	—
Feb 11 - Mar 24 in 15 mo	KPL-387	Phase 2	Recurrent Pericarditis; Heart Diseases; Pericarditis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ARCALYST (rilonacept)

Approved · Active

Target IL-1α/IL-1β

Partnerships Regeneron: exclusive license (BLA transferred after RHAPSODY Phase 3); Huadong: exclusive rights to develop/commercialize ARCALYST in China/Hong Kong/Macao/Taiwan and SE/South Asia territory (upfront $12M, $20M regulatory milestone owed in 2024, up to ~$50M sales milestones, tiered royalties)

Indications

Recurrent pericarditis (reduction in risk of recurrence, adults and children 12+) (Approved)
Cryopyrin-Associated Periodic Syndromes (Approved)
Deficiency of Interleukin-1 Receptor Antagonist (Approved)

Status note FDA approved March 2021 for recurrent pericarditis and reduction in risk of recurrence (adults and children 12+). Company assumed US sales/distribution for CAPS and DIRA. ARCALYST is a registered trademark of Regeneron.

KPL-387

Stage not disclosed · Active Modality: Monoclonal antibody (fully human IgG2)

Target IL-1R1 (interleukin-1 receptor 1; inhibits IL-1alpha/IL-1beta signaling)

Partnerships n/a (independently developed)

Indications

Recurrent pericarditis (Stage not disclosed)

Status note Filing states the company expects to begin commercializing KPL-387 in 2028 or 2029. Trial-phase and data-timing details appear only in the 10-K fallback section of the source material, not the primary 10-Q.

KPL-1161

Preclinical · Active Modality: Monoclonal antibody (Fc-modified IgG2)

Target IL-1R1 (interleukin-1 receptor 1; inhibits IL-1alpha/IL-1beta signaling)

Partnerships n/a (independently developed)

Indications

not disclosed (Preclinical)

Status note Preclinical, modified version of KPL-387 designed for increased half-life supporting potential quarterly SC dosing. Company plans to initiate a Phase 1 first-in-human trial by end of 2026.

Abiprubart

Phase 2 · Terminated Modality: Monoclonal antibody

Target CD40-CD154 costimulatory interaction

Partnerships Beth Israel Deaconess Medical Center: exclusive worldwide license

Indications

Sjogren's Disease (Phase 2)

Status note Feb 2025: company announced plans to discontinue development of abiprubart in Sjogren's Disease (was a Phase 2b trial) and to explore strategic alternatives for the asset. Clinical supply agreements with CDMOs terminated (Feb 2025).

Per-asset detail extracted from the 10-Q filed 2026-07-28. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	KPL-387
Lead indication	Pericarditis
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07010159	Phase 3	Recruiting	Sponsor	KNSA	—	Pericarditis; Pericarditis Acute; Recurrent Pericarditis	—
NCT07288216	Phase 2	Recruiting	Sponsor	KNSA	—	Recurrent Pericarditis; Heart Diseases; Pericarditis	—
NCT04687358	Not disclosed	Active, not recruiting	Sponsor	KNSA	—	Recurrent Pericarditis	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Kiniksa Pharmaceuticals International, plc on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	2,834,643	+8,397	0.91%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

KNSA — Kiniksa Pharmaceuticals International plc ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

KNSA — Kiniksa Pharmaceuticals International plc